Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells

Bing Z. Carter, Po Yee Mak, Hong Mu, Hongsheng Zhou, Duncan H. Mak, Wendy Schober, Joel D. Leverson, Bin Zhang, Ravi Bhatia, Xuelin Huang, Jorge Cortes, Hagop Kantarjian, Marina Konopleva, Michael Andreeff

Research output: Contribution to journalArticle

Abstract

BCR-ABL tyrosine kinase inhibitors (TKIs) are effective against chronic myeloid leukemia (CML), but they rarely eliminate CML stem cells. Disease relapse is common upon therapy cessation, even in patients with complete molecular responses. Furthermore, once CML progresses to blast crisis (BC), treatment outcomes are dismal. We hypothesized that concomitant targeting of BCL-2 and BCR-ABL tyrosine kinase could overcome these limitations. We demonstrate increased BCL-2 expression at the protein level in bone marrow cells, particularly in Lin-Sca-1+cKit+ cells of inducible CML in mice, as determined by CyTOF mass cytometry. Further, selective inhibition of BCL-2, aided by TKI-mediated MCL-1 and BCL-XL inhibition, markedly decreased leukemic Lin-Sca-1+cKit+ cell numbers and long-term stem cell frequency and prolonged survival in a murine CML model. Additionally, this combination effectively eradicated CD34+CD38-, CD34+CD38+, and quiescent stem/progenitor CD34+ cells from BC CML patient samples. Our results suggest that BCL-2 is a key survival factor for CML stem/progenitor cells and that combined inhibition of BCL-2 and BCR-ABL tyrosine kinase has the potential to significantly improve depth of response and cure rates of chronic-phase and BC CML.

Original languageEnglish (US)
Article number355ra117
JournalScience Translational Medicine
Volume8
Issue number355
DOIs
StatePublished - Sep 7 2016

Fingerprint

Myeloid Progenitor Cells
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Blast Crisis
Stem Cells
TYK2 Kinase
Survival
Bone Marrow Cells
Cell Count
Recurrence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Carter, B. Z., Mak, P. Y., Mu, H., Zhou, H., Mak, D. H., Schober, W., ... Andreeff, M. (2016). Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Science Translational Medicine, 8(355), [355ra117]. https://doi.org/10.1126/scitranslmed.aag1180

Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. / Carter, Bing Z.; Mak, Po Yee; Mu, Hong; Zhou, Hongsheng; Mak, Duncan H.; Schober, Wendy; Leverson, Joel D.; Zhang, Bin; Bhatia, Ravi; Huang, Xuelin; Cortes, Jorge; Kantarjian, Hagop; Konopleva, Marina; Andreeff, Michael.

In: Science Translational Medicine, Vol. 8, No. 355, 355ra117, 07.09.2016.

Research output: Contribution to journalArticle

Carter, BZ, Mak, PY, Mu, H, Zhou, H, Mak, DH, Schober, W, Leverson, JD, Zhang, B, Bhatia, R, Huang, X, Cortes, J, Kantarjian, H, Konopleva, M & Andreeff, M 2016, 'Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells', Science Translational Medicine, vol. 8, no. 355, 355ra117. https://doi.org/10.1126/scitranslmed.aag1180
Carter, Bing Z. ; Mak, Po Yee ; Mu, Hong ; Zhou, Hongsheng ; Mak, Duncan H. ; Schober, Wendy ; Leverson, Joel D. ; Zhang, Bin ; Bhatia, Ravi ; Huang, Xuelin ; Cortes, Jorge ; Kantarjian, Hagop ; Konopleva, Marina ; Andreeff, Michael. / Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. In: Science Translational Medicine. 2016 ; Vol. 8, No. 355.
@article{b4ba2b92cfa84120888cb6607db6cbc7,
title = "Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells",
abstract = "BCR-ABL tyrosine kinase inhibitors (TKIs) are effective against chronic myeloid leukemia (CML), but they rarely eliminate CML stem cells. Disease relapse is common upon therapy cessation, even in patients with complete molecular responses. Furthermore, once CML progresses to blast crisis (BC), treatment outcomes are dismal. We hypothesized that concomitant targeting of BCL-2 and BCR-ABL tyrosine kinase could overcome these limitations. We demonstrate increased BCL-2 expression at the protein level in bone marrow cells, particularly in Lin-Sca-1+cKit+ cells of inducible CML in mice, as determined by CyTOF mass cytometry. Further, selective inhibition of BCL-2, aided by TKI-mediated MCL-1 and BCL-XL inhibition, markedly decreased leukemic Lin-Sca-1+cKit+ cell numbers and long-term stem cell frequency and prolonged survival in a murine CML model. Additionally, this combination effectively eradicated CD34+CD38-, CD34+CD38+, and quiescent stem/progenitor CD34+ cells from BC CML patient samples. Our results suggest that BCL-2 is a key survival factor for CML stem/progenitor cells and that combined inhibition of BCL-2 and BCR-ABL tyrosine kinase has the potential to significantly improve depth of response and cure rates of chronic-phase and BC CML.",
author = "Carter, {Bing Z.} and Mak, {Po Yee} and Hong Mu and Hongsheng Zhou and Mak, {Duncan H.} and Wendy Schober and Leverson, {Joel D.} and Bin Zhang and Ravi Bhatia and Xuelin Huang and Jorge Cortes and Hagop Kantarjian and Marina Konopleva and Michael Andreeff",
year = "2016",
month = "9",
day = "7",
doi = "10.1126/scitranslmed.aag1180",
language = "English (US)",
volume = "8",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "355",

}

TY - JOUR

T1 - Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells

AU - Carter, Bing Z.

AU - Mak, Po Yee

AU - Mu, Hong

AU - Zhou, Hongsheng

AU - Mak, Duncan H.

AU - Schober, Wendy

AU - Leverson, Joel D.

AU - Zhang, Bin

AU - Bhatia, Ravi

AU - Huang, Xuelin

AU - Cortes, Jorge

AU - Kantarjian, Hagop

AU - Konopleva, Marina

AU - Andreeff, Michael

PY - 2016/9/7

Y1 - 2016/9/7

N2 - BCR-ABL tyrosine kinase inhibitors (TKIs) are effective against chronic myeloid leukemia (CML), but they rarely eliminate CML stem cells. Disease relapse is common upon therapy cessation, even in patients with complete molecular responses. Furthermore, once CML progresses to blast crisis (BC), treatment outcomes are dismal. We hypothesized that concomitant targeting of BCL-2 and BCR-ABL tyrosine kinase could overcome these limitations. We demonstrate increased BCL-2 expression at the protein level in bone marrow cells, particularly in Lin-Sca-1+cKit+ cells of inducible CML in mice, as determined by CyTOF mass cytometry. Further, selective inhibition of BCL-2, aided by TKI-mediated MCL-1 and BCL-XL inhibition, markedly decreased leukemic Lin-Sca-1+cKit+ cell numbers and long-term stem cell frequency and prolonged survival in a murine CML model. Additionally, this combination effectively eradicated CD34+CD38-, CD34+CD38+, and quiescent stem/progenitor CD34+ cells from BC CML patient samples. Our results suggest that BCL-2 is a key survival factor for CML stem/progenitor cells and that combined inhibition of BCL-2 and BCR-ABL tyrosine kinase has the potential to significantly improve depth of response and cure rates of chronic-phase and BC CML.

AB - BCR-ABL tyrosine kinase inhibitors (TKIs) are effective against chronic myeloid leukemia (CML), but they rarely eliminate CML stem cells. Disease relapse is common upon therapy cessation, even in patients with complete molecular responses. Furthermore, once CML progresses to blast crisis (BC), treatment outcomes are dismal. We hypothesized that concomitant targeting of BCL-2 and BCR-ABL tyrosine kinase could overcome these limitations. We demonstrate increased BCL-2 expression at the protein level in bone marrow cells, particularly in Lin-Sca-1+cKit+ cells of inducible CML in mice, as determined by CyTOF mass cytometry. Further, selective inhibition of BCL-2, aided by TKI-mediated MCL-1 and BCL-XL inhibition, markedly decreased leukemic Lin-Sca-1+cKit+ cell numbers and long-term stem cell frequency and prolonged survival in a murine CML model. Additionally, this combination effectively eradicated CD34+CD38-, CD34+CD38+, and quiescent stem/progenitor CD34+ cells from BC CML patient samples. Our results suggest that BCL-2 is a key survival factor for CML stem/progenitor cells and that combined inhibition of BCL-2 and BCR-ABL tyrosine kinase has the potential to significantly improve depth of response and cure rates of chronic-phase and BC CML.

UR - http://www.scopus.com/inward/record.url?scp=84988805216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988805216&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.aag1180

DO - 10.1126/scitranslmed.aag1180

M3 - Article

C2 - 27605552

AN - SCOPUS:84988805216

VL - 8

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 355

M1 - 355ra117

ER -